Moderna (MRNA) Free Cash Flow (2018 - 2026)

Moderna (MRNA) has 9 years of Free Cash Flow data on file, last reported at -$692.0 million in Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$692.0 million, up 36.34% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.7 billion (up 46.27% YoY), and the FY2025 annual result was -$2.1 billion, up 33.41% from the prior year.
• Free Cash Flow fell to -$692.0 million in Q1 2026 per MRNA's latest filing, from $891.0 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $2.6 billion in Q1 2022 and troughed at -$1.6 billion in Q3 2023.
• A 5-year average of -$246.9 million and a median of -$916.0 million in 2025 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2023 and 2025: Free Cash Flow tumbled 524.88% in 2023, then surged 41.32% in 2025.
• A 5-year view of Free Cash Flow shows it stood at $1.7 billion in 2022, then tumbled by 61.68% to $640.0 million in 2023, then increased by 25.94% to $806.0 million in 2024, then gained by 10.55% to $891.0 million in 2025, then plunged by 177.67% to -$692.0 million in 2026.
• Business Quant data shows MRNA's Free Cash Flow at -$692.0 million in Q1 2026, $891.0 million in Q4 2025, and -$953.0 million in Q3 2025.